Skip to content
Xeris Biopharma Holdings, Inc. (XERS) Insider Trading
Home / Companies / XERS XER
Xeris Biopharma Holdings, Inc. (XERS) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest XERS Insider Trades
About Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Headquarters CHICAGO, IL
Employees 435
Listed 2018
Exchange XNAS https://www.xerispharma.com SEC filings for XERS on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 12 271,499 $2.04M Grant or award 14 414,626 Tax withholding / forfeiture 2 58,563
XERS Insider Transactions (Form 4) 71 42 Form 4 filings on record, the earliest from Nov 26, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Aug 1, 2026 JJ John Patrick Shannon Jr. - Officer Tax withholding / forfeiture Common Stock
Recent XERS Form 8-K Filings 5
Recent XERS Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 12, 2026 STEVEN PIEPER Officer 20,000 $168K View on EDGAR Jul 7, 2026 - -
XERS Insider Trading - FAQ
What is the latest insider trade for XERS? Xeris Biopharma Holdings, Inc. (XERS) had 16 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for XERS runs to 42 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying XERS stock? No insider purchases of XERS were filed in the last 90 days.
How many insiders are selling XERS stock? 12 insider sales of XERS were filed in the last 90 days, totaling $2.04M.
Where can I see XERS SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks XERS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow XERS insider buys? Create a free InsiderAlpha account and press Watch on this page to add XERS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track XERS insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free $120K
BH Beth Hecht - Officer Open-market sale $134K
Aug 3, 2026
BH Beth Hecht - Officer Open-market sale $134K
Jul 1, 2026
Market cap $1.55B
P/E ratio -
Dividend yield -
Average volume 1.87M
52 week high $10.08
52 week low $5.25
Today's high $8.68
Today's low $8.37
Open $8.62
Volume 1.03M
Previous close $8.60
Shares outstanding 182.32M Market cap
$1.55B
435 employees
XERS Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 12 sales totaling $2.04M.
Most-Active XERS Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 1, 2026 KM Kevin McCulloch - Officer Tax withholding / forfeiture Common Stock 21,918 $8.08 $177K
Aug 12, 2026 SP Steven Pieper - Officer Open-market sale Common Stock 5,000 $8.50 $43K
Aug 3, 2026 KM Kevin McCulloch - Officer Open-market sale Common Stock 15,000 $8.02 $120K
Aug 3, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,666 $8.01 $134K
Jul 6, 2026 SP Steven Pieper - Officer Open-market sale Common Stock 17,400 $8.50 $148K
Jul 7, 2026 SP Steven Pieper - Officer Open-market sale Common Stock 27,600 $8.52 $235K
Jul 1, 2026 NK Nerissa Kreher - Director Grant or award Common Stock 33,582 $0.00 -
Jul 1, 2026 NK Nerissa Kreher - Director Grant or award Stock Option (Right to Buy) 37,910 $8.00 $303K
Jul 1, 2026 KM Kevin McCulloch - Officer Open-market sale Common Stock 90,000 $8.03 $723K
Jul 1, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,666 $8.03 $134K
Jun 4, 2026 GK Garheng Kong - Director Grant or award Common Stock 24,193 $0.00 -
Jun 4, 2026 GK Garheng Kong - Director Grant or award Stock Option (Right to Buy) 32,996 $6.15 $203K
Jun 3, 2026 MP Marla Persky - Director Open-market sale Common Stock 15,500 $5.90 $91K
Jun 4, 2026 MP Marla Persky - Director Grant or award Common Stock 24,193 $0.00 -
Jun 4, 2026 MP Marla Persky - Director Grant or award Stock Option (Right to Buy) 32,996 $6.15 $203K
Jun 4, 2026 DH Dawn Halkuff - Director Open-market sale Common Stock 20,000 $6.09 $122K
Jun 4, 2026 DH Dawn Halkuff - Director Grant or award Common Stock 24,193 $0.00 -
Jun 4, 2026 DH Dawn Halkuff - Director Grant or award Stock Option (Right to Buy) 32,996 $6.15 $203K
Jun 4, 2026 JJ John Johnson - Director Open-market sale Common Stock 15,000 $6.09 $91K
Jun 4, 2026 JJ John Johnson - Director Grant or award Common Stock 24,193 $0.00 -
Jun 4, 2026 JJ John Johnson - Director Grant or award Stock Option (Right to Buy) 32,996 $6.15 $203K
Jun 4, 2026 JB James Aloysius Brady - Director Grant or award Stock Option (Right to Buy) 32,996 $6.15 $203K
Jun 1, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,667 $6.06 $101K
May 1, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,667 $6.23 $104K
Apr 1, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,667 $5.99 $100K
Mar 12, 2026 KM Kevin McCulloch - Officer Option exercise Common Stock 48,894 $4.09 $200K
Mar 12, 2026 KM Kevin McCulloch - Officer Option exercise Common Stock 4 $3.94 $16
Mar 12, 2026 KM Kevin McCulloch - Officer Option exercise Stock Option (Right to Buy) 48,894 $4.09 $200K
Mar 12, 2026 KM Kevin McCulloch - Officer Option exercise Stock Option (Right to Buy) 4 $3.94 $16
Mar 5, 2026 SP Steven Pieper - Officer Option exercise Common Stock 27,891 $4.09 $114K
Mar 5, 2026 SP Steven Pieper - Officer Option exercise Common Stock 14,036 $5.93 $83K
Mar 5, 2026 SP Steven Pieper - Officer Option exercise Stock Option (Right to Buy) 27,891 $0.00 -
Mar 5, 2026 SP Steven Pieper - Officer Option exercise Stock Option (Right to Buy) 14,036 $0.00 -
Mar 2, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,567 $6.24 $103K
Mar 2, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 100 $7.06 $706
Feb 24, 2026 AN Anh Tu Nguyen - Officer Tax withholding / forfeiture Common Stock 29,300 $6.88 $202K
Jan 31, 2026 KM Kevin McCulloch - Officer Tax withholding / forfeiture Common Stock 68,454 $7.36 $504K
Jan 31, 2026 KM Kevin McCulloch - Officer Tax withholding / forfeiture Common Stock 30,289 $7.36 $223K
Jan 31, 2026 KM Kevin McCulloch - Officer Tax withholding / forfeiture Common Stock 27,319 $7.36 $201K
Jan 30, 2026 KM Kevin McCulloch - Officer Grant or award Stock Option (Right to Buy) 225,225 $0.00 -
Jan 30, 2026 KM Kevin McCulloch - Officer Grant or award Common Stock 168,463 $0.00 -
Jan 30, 2026 SP Steven Pieper - Officer Grant or award Common Stock 154,986 $0.00 -
Jan 31, 2026 SP Steven Pieper - Officer Tax withholding / forfeiture Common Stock 111,765 $7.36 $823K
Jan 31, 2026 SP Steven Pieper - Officer Tax withholding / forfeiture Common Stock 66,450 $7.36 $489K
Jan 31, 2026 SP Steven Pieper - Officer Tax withholding / forfeiture Common Stock 27,319 $7.36 $201K
Jan 30, 2026 SP Steven Pieper - Officer Grant or award Stock Option (Right to Buy) 207,207 $0.00 -
Jan 30, 2026 AN Anh Tu Nguyen - Officer Grant or award Common Stock 121,293 $0.00 -
Jan 30, 2026 AN Anh Tu Nguyen - Officer Grant or award Stock Option (Right to Buy) 162,162 $0.00 -
Jan 30, 2026 BH Beth Hecht - Officer Grant or award Common Stock 121,293 $0.00 -
Jan 31, 2026 BH Beth Hecht - Officer Tax withholding / forfeiture Common Stock 98,375 $7.36 $724K
Jan 31, 2026 BH Beth Hecht - Officer Tax withholding / forfeiture Common Stock 46,914 $7.36 $345K
Jan 31, 2026 BH Beth Hecht - Officer Tax withholding / forfeiture Common Stock 24,266 $7.36 $179K
Feb 2, 2026 BH Beth Hecht - Officer Open-market sale Common Stock 16,667 $7.45 $124K
Jan 30, 2026 BH Beth Hecht - Officer Grant or award Stock Option (Right to Buy) 162,162 $0.00 -
Dec 1, 2025 BH Beth Hecht - Officer Open-market sale Common Stock 16,667 $7.01 $117K
$YMAB
Y-mAbs Therapeutics, Inc.
$IONS
IONIS PHARMACEUTICALS INC
